These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 9270057

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D, Kusunoki M, Shinzawa G, Feng Z, Nishina A, Nakamura T.
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [Abstract] [Full Text] [Related]

  • 6. Effects of cilostazol on the peripheral nerve function and structure in STZ-induced diabetic rats.
    Uehara K, Sugimoto K, Wada R, Yoshikawa T, Marukawa K, Yasuda Y, Kimura Y, Yagihashi S.
    J Diabetes Complications; 1997 Dec; 11(3):194-202. PubMed ID: 9174902
    [Abstract] [Full Text] [Related]

  • 7. An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.
    Hara T, Nakamura J, Koh N, Sakakibara F, Hamada Y, Sasaki H, Naruse K, Nakashima E, Takeuchi N, Inukai S.
    J Lab Clin Med; 1995 Dec; 126(6):541-7. PubMed ID: 7490513
    [Abstract] [Full Text] [Related]

  • 8. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
    Kashima K, Sato N, Sato K, Shimizu H, Mori M.
    Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
    [Abstract] [Full Text] [Related]

  • 9. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K, Kato N, Makino M, Suzuki T, Shindo M.
    J Diabetes Complications; 1999 Aug; 13(3):141-50. PubMed ID: 10509874
    [Abstract] [Full Text] [Related]

  • 10. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Kikkawa R, Hatanaka I, Yasuda H, Kobayashi N, Shigeta Y.
    Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
    [Abstract] [Full Text] [Related]

  • 11. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
    Hotta N, Koh N, Sakakibara F, Nakamura J, Hamada Y, Wakao T, Hara T, Mori K, Naruse K, Nakashima E, Sakamoto N.
    J Pharmacol Exp Ther; 1996 Jan; 276(1):49-55. PubMed ID: 8558455
    [Abstract] [Full Text] [Related]

  • 12. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
    Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, Hirata T, Saruta T, Shimada A, Itoh H.
    J Diabetes Complications; 2010 Jan; 24(6):424-32. PubMed ID: 19716319
    [Abstract] [Full Text] [Related]

  • 13. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
    Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kikkawa R.
    Biomed Pharmacother; 1995 Jan; 49(6):269-77. PubMed ID: 7579007
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE, Cotter MA, Basso M, Hohman TC.
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [Abstract] [Full Text] [Related]

  • 15. Aldose reductase inhibitor ONO-2235 restores the alterations of bladder nerve growth factor and neurotrophin receptor p75 genetic expression in streptozotocin induced diabetic rats.
    Tong YC, Cheng JT.
    J Urol; 2007 Nov; 178(5):2203-7. PubMed ID: 17870109
    [Abstract] [Full Text] [Related]

  • 16. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y.
    Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
    [Abstract] [Full Text] [Related]

  • 17. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats.
    Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ.
    Diabetes; 1990 Jun; 39(6):690-6. PubMed ID: 2140802
    [Abstract] [Full Text] [Related]

  • 18. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA, Cameron NE, Hohman TC.
    J Peripher Nerv Syst; 1998 Jun; 3(3):217-23. PubMed ID: 10959252
    [Abstract] [Full Text] [Related]

  • 19. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N, Kawamori R, Fukuda M, Shigeta Y, Aldose Reductase Inhibitor-Diabetes Complications Trial Study Group.
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [Abstract] [Full Text] [Related]

  • 20. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA, Borja NL.
    Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.